Ultragenyx - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeUltragenyx
Ultragenyx logo

Ultragenyx

0 followers

RARE

Performance

About Ultragenyx

Ultragenyx is a biopharmaceutical company focused on developing first-ever approved treatments for rare and ultrarare genetic diseases and advancing therapies to move the rare disease community forward. The company operates with a global pipeline across multiple indications, including glycogen storage disease type Ia, OTC deficiency, Wilson disease, osteogenesis imperfecta, Angelman syndrome, MPS IIIA, and CDD, among others. Its research emphasizes novel modalities and comprehensive development and commercialization strategies to deliver transformative medicines for patients with limited or no existing options.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Emil D. Kakkis, M.D., Ph.D.

Founder, President and Chief Executive Officer

Eric Olson

Chief Business Officer and Executive Vice President

John Pinion

Chief Quality Operations Officer and Executive Vice President, Translational Sciences

Ernie Meyer

Chief Human Resources Officer and Executive Vice President

Howard Horn

Chief Financial Officer and Executive Vice President, Corporate Strategy

Key Facts

HQ Location

San Francisco, United States

Founded

2010

Employees

1K-5K

Status

Public

Website

https://ultragenyx.com